[EN] SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] COMBINAISON SYNERGIQUE D'INHIBITEURS IMMUNOLOGIQUES POUR LE TRAITEMENT DU CANCER
申请人:UNIV CHICAGO
公开号:WO2014066834A1
公开(公告)日:2014-05-01
In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7. The inventors particularly observed a major synergistic effect of combining anti-CTLA-4 with either an IDO inhibitor, with anti-PD-L1 mAb, or with CD-25 depletion. Such combinations have been found to demonstrate a synergistic effect in treating cancer and tumors, for example by reducing tumor size, increasing the percentage of antigen-specific T cells, and increasing T cell function.
1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase
申请人:Incyte Corporation
公开号:US20150190378A1
公开(公告)日:2015-07-09
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase
申请人:Combs Andrew P.
公开号:US20120058079A1
公开(公告)日:2012-03-08
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
申请人:Incyte Corporation
公开号:US08088803B2
公开(公告)日:2012-01-03
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase
申请人:Combs Andrew P.
公开号:US20140023663A1
公开(公告)日:2014-01-23
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.